Immix Biopharma Expands U.S. Clinical Trial Sites For NEXICART-2 In Relapsed/Refractory AL Amyloidosis
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma is expanding its U.S. clinical trial sites for NEXICART-2, a treatment for relapsed/refractory AL Amyloidosis. New sites include Cleveland Clinic, UC Davis, and Sutter Health, with MSKCC as the lead site. Ex-U.S. data shows a 92% response rate.
August 28, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma is expanding its clinical trial sites for NEXICART-2 in the U.S., adding prestigious institutions like Cleveland Clinic, UC Davis, and Sutter Health. The lead site remains MSKCC, with promising ex-U.S. data showing a 92% response rate.
The expansion of clinical trial sites to include well-known institutions like Cleveland Clinic and UC Davis suggests increased confidence and potential for successful trial outcomes. The high response rate from ex-U.S. data further supports a positive outlook for the drug's development, likely boosting investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100